Doripenem population pharmacokinetics and dosing requirements for critically ill patients receiving continuous venovenous haemodiafiltration

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 9, 2014, Pages 2508-2516

  Roberts, Jason A ^a,b   Udy, Andrew A ^a,b   Bulitta, Juergen B ^c   Stuart, Janine ^b   Jarrett, Paul ^b   Starr, Therese ^b   Lassig Smith, Melissa ^b   Roberts, Natasha A ^b   Dunlop, Rachel ^b   Hayashi, Yoshiro ^a,d,e   Wallis, Steven C ^a   Lipman, Jeffrey ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d KAMEDA MEDICAL CENTER   (Japan)

^e UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Carbapenems; Continuous renal replacement therapy; CRRT; Intensive care; Pharmacodynamics; Sepsis; lactams

Indexed keywords

DORIPENEM; POLYACRYLONITRILE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BLOOD FILTER; BLOOD SAMPLING; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS INFUSION; CRITICALLY ILL PATIENT; DIALYSATE; DRUG CLEARANCE; DRUG DISTRIBUTION; FEMALE; HEMODIALYSIS MACHINE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; OBSERVATIONAL STUDY; RENAL REPLACEMENT THERAPY; ACUTE KIDNEY INJURY; CHEMISTRY; CRITICAL ILLNESS; HEMODIAFILTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; MIDDLE AGED; PLASMA; VERY ELDERLY; YOUNG ADULT;

ACUTE KIDNEY INJURY; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CRITICAL ILLNESS; FEMALE; HEMODIAFILTRATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PLASMA; YOUNG ADULT;

EID: 84905978802     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku177     Document Type: Article

References (43)

1. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294: 813-8.
2. Bagshaw SM, Uchino S, Bellomo R, et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol 2007; 2: 431-9.
3. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31: 345-51.
4. Li C, Du X, Kuti JL, et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007; 51: 1725-30.
5. Lodise TP Jr, Lomaestro B, Drusano GL. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 2007; 44: 357-63.
6. Lorente L, Huidobro S, Martín M, et al. Meropenem administration by intermittent infusion versus continuous infusion for the treatment of nosocomial pneumonia. Crit Care 2005; 9: P38.
7. Lorente L, Jimenez A, Martin MM, et al. Clinical cure of ventilatorassociated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents 2009; 33: 464-8.
8. Jamal JA, Economou CJ, Lipman J, et al. Improving antibiotic dosing in special situations in the ICU: burns, renal replacement therapy and extracorporeal membrane oxygenation. Curr Opin Crit Care 2012; 18: 460-71.
9. Roberts DM, Roberts JA, Roberts MS, et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy-a multicentre pharmacokinetic study. Crit Care Med 2012; 40: 1523-8.
10. Paterson DL, Depestel DD. Doripenem. Clin Infect Dis 2009; 49: 291-8.
11. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of "bug and drug". Nat Rev Microbiol 2004; 2: 289-300.
12. Roberts JA, Lipman J. Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med 2013; 41: 489-95.
13. Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care 2012; 16: R218.
14. Milatovic D, Braveny I. Development of resistance during antibiotic therapy. Eur J Clin Microbiol 1987; 6: 234-44.
15. KnausWA, Draper EA,Wagner DP, et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
16. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/ Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
17. Anon. Guidance for Industry-Bioanalytical Method Validation. Rockville, MD: Center for Drug Evaluation and Research (CDER), 2001.
18. Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9: E60-83.
19. Bulitta JB, Bingolbali A, Shin BS, et al. Development of a new pre- and post-processing tool (SADAPT-TRAN) for nonlinear mixed-effects modeling in S-ADAPT. AAPS J 2011; 13: 201-11.
20. Landersdorfer CB, Bulitta JB, Kirkpatrick CM, et al. Population pharmacokinetics of piperacillin at two dose levels: influence of nonlinear pharmacokinetics on the pharmacodynamic profile. Antimicrob Agents Chemother 2012; 56: 5715-23.
21. Bulitta JB, Kinzig M, Jakob V, et al. Nonlinear pharmacokinetics of piperacillin in healthy volunteers-implications for optimal dosage regimens. Br J Clin Pharmacol 2010; 70: 682-93.
22. Bulitta JB, Okusanya OO, Forrest A, et al. Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrob Agents Chemother 2013; 57: 498-507.
23. Bhalodi AA, Keel RA, Quintiliani R, et al. Pharmacokinetics of doripenem in infected patients treated within and outside the intensive care unit. Ann Pharmacother 2013; 47: 617-27.
24. Jaruratanasirikul S, Wongpoowarak W, Kositpantawong N, et al. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia. Int J Antimicrob Agents 2012; 40: 434-9.
25. Nandy P, Samtani MN, Lin R. Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients. Antimicrob Agents Chemother 2010; 54: 2354-9.
26. Cirillo I, Vaccaro N, Redman R, et al. Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis. J Clin Pharmacol 2012; 52: 1645-53.
27. Hidaka S, Goto K, Hagiwara S, et al. Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF). Yakugaku Zasshi 2010; 130: 87-94.
28. Samtani MN, Vaccaro N, Cirillo I, et al. Doripenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy. ISRN Pharmacol 2012; 2012: 782656.
29. Cirillo I, Vaccaro N, Balis D, et al. Influence of continuous venovenous hemofiltration and continuous venovenous hemodiafiltration on the disposition of doripenem. Antimicrob Agents Chemother 2011; 55: 1187-93.
30. Cirillo I, Mannens G, Janssen C, et al. Disposition, metabolism, and excretion of [14C]doripenem after a single 500-milligram intravenous infusion in healthy men. Antimicrob Agents Chemother 2008; 52: 3478-83.
31. Ohchi Y, Hidaka S, Goto K, et al. Effect of hemopurification rate on doripenem pharmacokinetics in critically ill patients receiving high-flow continuous hemodiafiltration. Yakugaku Zasshi 2011; 131: 1395-9.
32. Krueger WA, Schroeder TH, Hutchinson M, et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 1998; 42: 2421-4.
33. Valtonen M, Tiula E, Backman JT, et al. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2000; 45: 701-4.
34. Giles LJ, Jennings AC, Thomson AH, et al. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med 2000; 28: 632-7.
35. Krueger WA, Neeser G, Schuster H, et al. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration. Chemotherapy 2003; 49: 280-6.
36. Isla A, et al. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients. J Clin Pharmacol 2005; 45: 1294-304.
37. Langgartner J, Lehn N, Gluck T, et al. Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion. Chemotherapy 2007; 53: 370-7.
38. Udy AA, Roberts JA, De Waele JJ, et al. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance. Int J Antimicrob Agents 2012; 39: 455-7.
39. Lipman J, Udy AA, Roberts JA. Do we understand the impact of altered physiology, consequent interventions and resultant clinical scenarios in the intensive care unit? The antibiotic story. Anaesth Intensive Care 2011; 39: 999-1000.
40. Kiratisin P, Chongthaleong A, Tan TY, et al. Comparative in vitro activity of carbapenems against major Gram-negative pathogens: results of Asia-Pacific surveillance from the COMPACT II study. Int J Antimicrob Agents 2012; 39: 311-6.
41. Eagye KJ, Banevicius MA, Nicolau DP. Pseudomonas aeruginosa is not just in the intensive care unit any more: implications for empirical therapy. Crit Care Med 2012; 40: 1329-32.
42. Roberts JA, Roberts MS, Robertson TA, et al. Piperacillin penetration into tissue of critically ill patients with sepsis-bolus versus continuous administration? Crit Care Med 2009; 37: 926-33.
43. Roberts JA, Kirkpatrick CM, Roberts MS, et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64: 142-50.